Cancer

The papers listed here, have been cited in a substantially greater number of publications than others of the same type and vintage, according to data from the Science Citation Index® of the Institute for Scientific Information, Philadelphia. Why have these research reports become such standouts? In conversations with The Scientist, the authors attempt to provide answers. Following protein pathways can lead to unexpected places. In this case, three groups approached b-catenin from separate d

The Scientist Staff
Jul 4, 1999
The papers listed here, have been cited in a substantially greater number of publications than others of the same type and vintage, according to data from the Science Citation Index® of the Institute for Scientific Information, Philadelphia. Why have these research reports become such standouts? In conversations with The Scientist, the authors attempt to provide answers.


Following protein pathways can lead to unexpected places. In this case, three groups approached b-catenin from separate directions but soon found their trails crossing. The separate journeys converged in 1993 when Paul Polakis, then at Onyx Pharmaceuticals Inc. of Richmond, Calif., and Kenneth Kinzler's group at Johns Hopkins University independently reported that the tumor suppressor protein adenomatous polyposis coli (APC) bound b catenin.1,2 In 1995 Paul Polakis' group demonstrated this APC interaction could also down-regulate b-catenin.3

For years, scientists had known that b-catenin acted at the cell membrane as an...